PET Imaging Study on Occupancy of Dopamine D2 Receptors and Genotypes After Bupropion Administration

Seoul National University

Status and phase: Completed; Phase 4

Conditions: Smoking

Treatments: Drug: Bupropion

Study type: Interventional

Funder types: Other

Identifiers

NCT00846339

SNUCPT08_BUP1

Details and patient eligibility

About

Bupropion has different effects on D2 dopamine receptors according to genotype.

Full description

Open, one arm, single sequence, 2-period, study stratified into 2 DRD2 genotype groups For subjects who volunteer to cease smoking, genotypes are investigated. Twelve subjects are enrolled (6 - DRD2 Taq1A1 allele, 6 - DRD2 Taq1A2 homozygotes). Subjects receive baseline raclopride PET (High Specific Activity, Low Specific Activity).

• Period 1 Subjects receive 150 mg of bupropion SR every day. After 1 week of medication, pharmacokinetic and PET studies are performed.
• Period 2 Subjects receive 150 mg of bupropion SR twice a day. After 1 week of medication, pharmacokinetic and PET studies are performed.

Enrollment: 12 patients

Sex: Male

Ages: 20 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Active smoker (more than 10 cigarettes per day for the past 2 years)

Exclusion criteria

• Medical or psychiatric co-morbidity
• Hypersensitive to bupropion

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

12 participants in 2 patient groups

1

Experimental group

Description:

DRD2 Taq1A1 allele

Treatment:

Drug: Bupropion

2

Experimental group

Description:

DRD Taq1 A2 homozygote2

Treatment:

Drug: Bupropion